about arsanis

Redefining the Practice of Medicine for Serious Infections

Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections.

Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis’ monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption.

We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.

Arsanis was co-founded in 2010 by three infectious disease and industry veterans:

  • Eszter Nagy, MD, PhD, Chief Scientific Officer of Arsanis and Managing Director of Arsanis Biosciences GmbH;
  • Tillman U. Gerngross, PhD, Chairman of the Arsanis Board of Directors and CEO of Adimab; and
  • Errik B. Anderson, venture capitalist and President and Chief Operating Officer of Compass Therapeutics.

Learn more about our programs and pipeline of novel targeted mAbs.